Literature DB >> 2840910

DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.

G Schwartsmann1, G J Peters, E Laurensse, F C de Waal, A H Loonen, A Leyva, H M Pinedo.   

Abstract

DUP 785 (NSC 368390; Brequinar sodium) is a new inhibitor of pyrimidine de novo biosynthesis with antitumor activity against several experimental tumors. DUP 785 inhibits the mitochondrial enzyme dihydroorotate dehydrogenase, blocking the conversion of dihydroorotate to orotate. We examined the influence of exposure time to DUP 785 on its growth-inhibitory effects in L1210 murine leukemia and WiDR human adenocarcinoma cells and the effects of pyrimidine (deoxy) nucleosides on reversal of growth-inhibition. The results were correlated with changes in intracellular pyrimidine nucleotide pools and cell cycle distribution. In L1210 cells, a continuous exposure to 25 microM DUP 785 up to 96 hr caused complete growth inhibition. A 2 hr exposure of cells to the drug did not affect growth. In WiDR cells, exposure to the drug for 1-24 hr, followed by cultivation in drug-free medium resulted in recovery of growth. However, cells exposed to the drug for 48 hr or longer were not able to resume growth when recultured in drug-free medium. Reversal studies were performed to know whether selective depletion of one of the pyrimidine (deoxy) nucleotides might be related to the growth-inhibitory effects of DUP 785. Neither thymidine, deoxycytidine alone, deoxycytidine plus tetrahydrouridine; nor cytidine plus tetrahydrouridine added after 24 hr were able to reverse cell growth inhibition induced by 25 microM DUP 785. However, uridine and cytidine alone reversed growth inhibition. UTP and CTP pools in L1210 cells decreased to about 30-40% of control levels after 4 hr of drug exposure, while dTTP and dCTP pools decreased to about 30% of control levels. There were no significant changes in purine nucleotide pools. In WiDR cells, UTP and CTP pools decreased rapidly after drug exposure and were substantially depleted after 24 hr. Reculture of cells in drug-free medium resulted in a significant recovery of UTP and CTP levels only for cells exposed to DUP 785 for 1-24 hr. For cells exposed to the drug for 48 and 72 hr recovery of nucleotide pools was minimal. In L1210 cells, a 12-hr exposure to the drug caused an accumulation of cells in the early S-phase. In WiDR cells, there was a clear accumulation of cells in the S-phase of the cell cycle after 24 hr drug exposure.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2840910     DOI: 10.1016/0006-2952(88)90636-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  11 in total

1.  Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.

Authors:  S Urba; J Doroshow; C Cripps; F Robert; E Velez-Garcia; B Dallaire; D Adams; R Carlson; A Grillo-Lopez; J Gyves
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors.

Authors:  Christine R Cuthbertson; Hui Guo; Armita Kyani; Joseph T Madak; Zahra Arabzada; Nouri Neamati
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-23

Review 3.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

4.  Brequinar sodium inhibits interleukin-6-induced differentiation of a human B-cell line into IgM-secreting plasma cells.

Authors:  K Tamura; J Woo; M T Bakri; A W Thomson
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

5.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production.

Authors:  J Woo; B Lemster; K Tamura; T E Starzl; A W Thomson
Journal:  Transplantation       Date:  1993-08       Impact factor: 4.939

7.  Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.

Authors:  M Moore; J Maroun; F Robert; R Natale; J Neidhart; B Dallaire; R Sisk; J Gyves
Journal:  Invest New Drugs       Date:  1993-02       Impact factor: 3.850

8.  Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies.

Authors:  H A Burris; E Raymond; A Awada; J G Kuhn; T J O'Rourke; J Brentzel; W Lynch; S Y King; T D Brown; D D Von Hoff
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

9.  Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Authors:  G Schwartsmann; P Dodion; J B Vermorken; W W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; W J van der Vijgh; M B van Hennik
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.

Authors:  G J Peters; I Kraal; H M Pinedo
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.